Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Starting today, eligible patients can use GoodRx to self-pay for Ozempic ® and Wegovy ® pens for $499-per-month at over ...

Detailed price information for Goodrx Holdings Inc Cl A (GDRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Goodrx Holdings Inc Cl A (GDRX-Q) from The Globe and Mail including charting and trades.

Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales only rose 1.2% year on year to $203.1 million. Its non-GAAP profit of $0.09 per share was ...